Specialty Pharmacy

Top news of the day from across the health care landscape.

Belantamab mafodotin has the potential for durable responses in patients with multiple myeloma whose disease has relapsed or is resistant to standard therapies.

Top news of the day from across the health care landscape.

Because of the vulnerabilities of CDK4/6i-resistant tumors, researchers believe that it is imperative to improve the survival of this group of patients.

Two studies linked ozone levels and wood burning as a source of heat to an increased risk of developing chronic obstructive pulmonary disease.

Rita Nanda, MD, discusses various immunotherapy drugs in the pipeline and which she thinks will be approved next. This video was filmed December 11 at the 2019 San Antonio Breast Cancer Symposium.

The rise in value-based reimbursement models has required oncology care providers to assume an unprecedented level of accountability.

The decline in the cancer mortality rate attributed to immunotherapy methods, early detection, and treatment.

Top news of the day from across the health care landscape.

The diazepam nasal spray was granted 7 years of Orphan Drug Exclusivity by the FDA Office of Orphan Products Development.

The Supreme Court released their decision to review Rutledge v. Pharmaceutical Care Management Association, which could affect pharmacy benefits across the country.

Through the Ready, Set, PrEP program, qualified patients from across the United States can access PrEP medication for the prevention of HIV, for free.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

This medication is the first precision therapy approved to treat a genomically defined population of patients with GIST, according to Blueprint Medicines.

Top news of the day from across the health care landscape.

Micafungin injection is the first antifungal drug approved in the United States specifically for pediatric patients younger than 4 years of age with invasive candidiasis.

Secukinumab provided early and sustained resolution of enthesitis in patients with psoriatic arthritis based on post hoc analysis pooled data from the FUTURE trial.

Officials with the FDA have approved pembrolizumab (Keytruda, Merck) for the treatment of certain patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle invasive bladder cancer.

Top news of the day from across the health care landscape.

Study seeks to determine how HIV avoids the zinc-finger antiviral protein and how it binds the RNA.

There are some basic tips or tricks to getting the most out of your insurance plan and to maintain the care patients are accustomed to.

Manufacturers have selected AllianceRx Walgreens as their limited distribution drug partner for drugs that treat conditions such as myelofibrosis, cystic fibrosis, and non-metastatic castration-resistant prostate cancer.

An effective treatment plan for squamous cell carcinoma best undertaken by a group of practitioners.

Top news of the day from across the health care landscape.

Since 2004, the FDA has approved different treatments for advanced prostate cancer, adding almost 2-3 indications per year for the past 15 years.

A study suggests that even brief art-making interventions can be beneficial for stressed caregivers of patients with cancer.

Top news of the day from across the health care landscape.